Tobramycin injection (Nebcin)
Category:
Description:
Indications:
-
Bacterial
infections (P. aeruginosa,
Proteus species (including P.
mirabilis), M. morganii, E.
coli, P. vulgaris, Klebsiella-Enterobacter-Serratia group, Citrobacter species, Staphylococcus species)
-
Septicemia
(P. aeruginosa, E. coli,
Klebsiella species)
-
Lower
respiratory tract infections (P.
aeruginosa, E. coli, Klebsiella species, Enterobacter species, Serratia species, S. aureus)
-
Serious
bacterial infections of the CNS (meningitis)
-
Intra-abdominal
infections, including peritonitis (,
E. coli, Klebsiella species, Enterobacter species)
-
Skin,
bone and soft tissue infections (P.
aeruginosa, Proteus species,
E. coli, Klebsiella species, Enterobacter species, S. aureus)
-
Complicated
and recurrent urinary tract infections (P.
aeruginosa, Proteus species, E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, Providencia species, S.
aureus)
-
Cystic
fibrosis nebulization therapy (P.
aeruginosa)
Contraindications:
Precautions:
-
Pregnancy
category D
-
May
cause nephrotoxicity, therefore closely monitor renal function,
especially in elderly patients.
-
May
cause ototoxicity, therefore monitor hearing
-
Monitor
peak and trough serum concentrations
-
In
patients with extensive burns, altered pharmacokinetics may alter
serum concentrations.
-
May
produce hypomagnesemia, especially if poor or restricted diet.
-
Aminoglycosides
have neuromuscular blockade activity with a curare-like effect. Monitor patient’s neuromuscular function, especially in
patients with myasthenia gravis, parkinsonism or infant botulism.
-
Cystic
fibrosis patients may have altered pharmacokinetics, requiring reduced
dosages
Adverse
Reactions (Side Effects):
-
Central
and peripheral nervous system reactions: Headache, delerium,
confusion, lethargy
-
Gastrointestinal:
vomiting, nausea, anorexia, hypersalivation
-
Hematologic:
changes in reticulocyte counts, anemia, altered WBC counts
-
Hypersensitivity:
rash, urticaria, itching
-
Special
senses: dizziness, tinnitis, vertigo
-
Renal:
clinduria, oliguria, proteinuria, increased creatinine and BUN
-
Miscellaneous:
apnea, alopecia, joint pain
-
Pain
at injection site
-
Decreased
calcium, sodium, potassium and magnesium levels
|
Dosage:
-
Administered
by IM or IV injection or nebulization
-
Therapy
duration is generally 7-10 days
-
Dosages
based on patients ideal body weight
Adults: normal
renal function: 3mg/kg/day IV or IM in 3 equal doses every 8 hours |
Weight
(pounds) |
Weight
(kg) |
Q8 hour Dose (Moderate Infections) |
132 |
60 |
60 mg IM/IV |
154 |
70 |
70 mg IM/IV |
176 |
80 |
80 mg IM/IV |
198 |
90 |
90 mg IM/IV |
Serious infections:
5mg/kg/day divided into 3-4 equal doses |
Weight
(pounds) |
Weight
(kg) |
Q8 hour Dose (Serious Infections) |
132 |
60 |
100 mg IM/IV |
154 |
70 |
117 mg IM/IV |
176 |
80 |
133 mg IM/IV |
198 |
90 |
150 mg IM/IV |
|
Home
· Military Medicine
· Sick Call · Basic Exams
· Medical Procedures
· Lab and X-ray · The Pharmacy
· The Library · Equipment
· Patient Transport
· Medical Force
Protection · Operational Safety · Operational
Settings · Special
Operations · Humanitarian
Missions · Instructions/Orders · Other Agencies · Video Gallery
· Forms · Web Links · Acknowledgements
· Help · Feedback Approved for public release;
Distribution is unlimited. The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.
Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by The Brookside Associates, LLC. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
© 2015, Brookside Associates, LLC. All rights reserved
Other Brookside Products
|
|